Zevra Therapeutics, Inc. (ZVRA) Earnings Call Transcript & Summary
August 12, 2020
Earnings Call Speaker Segments
Jason Rando
executiveHello, good afternoon, and we appreciate you being on this call to go over KemPharm's Second Quarter 2020 Financial and Corporate Results. Prior to getting started, I want to point out to everyone listening that anything said on this call could include forward-looking statements involving risks and uncertainties that may shift at any moment, such as, though not restricted to, statements concerning KemPharm's expectations about future operating results. These forward-looking statements are issued under the safe harbor provisions of the federal securities laws and reflect management's current expectations. Actual results could differ materially. KemPharm accepts no obligation to update or revise its forward-looking statements, except as required by law. Additional details on forward-looking statements, risks and uncertainties are available in the reports KemPharm files with the SEC, which can be accessed on KemPharm's website at www.kempharm.com in the Investor Relations section. We ask that you review these documents carefully. On today's call, Travis Mickle, KemPharm's President and CEO, and LaDuane Clifton, CFO, will be speaking. After their remarks, we'll open the call to questions. With that, I'm happy to introduce Travis.
Travis Mickle
executiveJason, thank you, and thanks to all of you for being on today's call. As lots of you have already observed or learned during the past quarter, we've made quite a few strides forward on our roadmap for KemPharm over the quarters ahead. To begin with the most important item, the FDA did accept the NDA for KP415, our lead product, and we collected the $5 million milestone payment from our partner, < >/GPC. Along with that, the Day-74 Letter arrived from the FDA, which set March 2 as the PDUFA date, and it also informed us that an Advisory Committee is not expected to be needed at this point. We further announced that Corium, which is a GPC portfolio company, will in fact take the lead on commercializing KP415. I'll get into this in somewhat more depth, but this is a very seasoned organization, headed by numerous people who previously served as Shire executives; on top of that, we announced not long ago that 2 patents had been granted, which adds 5 more years of patent life for serdexmethylphenidate, the prodrug contained in both KP415 and KP484. I'm going to ask LaDuane Clifton to walk through our highlights — the financial highlights, that is, plus an update on our stronger financial position.
R. Clifton
executiveAppreciate that, Travis. Beyond the regulatory and product news we just covered, the numbers we turned in for Q2 were quite strong as well. Revenue came in at $6.9 million. That marks our fourth quarter in a row of generating services revenue, split between the $5 million milestone payment and $1.9 million from services. From there we reached net income of nearly $1 million, or $0.01 per share, which is great too. We closed out the quarter holding $6.6 million in cash, a solid bump up from our position at the close of Q1. Thanks to the revenue plus a smaller expense base, our projected cash burn has come down to $1 million a quarter or less. And since the principal interest payments on our debt have been deferred until March 31, '21, all of this combined means our cash runway now stretches to the debt maturity date — again March 31, '21 — and past the PDUFA date for KP415.
Travis Mickle
executiveAppreciate that, LaDuane. To give a bit more detail on where things stand with KP415 on the regulatory and commercial planning side, I brought up the PDUFA date and the Advisory Committee. During our previous call, I noted that at some stage we intended to hold a mid-cycle review meeting with the FDA. That has now been placed on the calendar for tomorrow. Naturally, should anything pertinent come out of that meeting, we'd share it through a press release afterward. Along with the news that Corium has taken on the lead role for commercialization, we're still bringing in consultation fees through this commercialization arrangement, plus consulting fees from Corium. On top of that, we do intend to hold a discussion. It would take the form of a hosted webcast investor and analyst call, where the leadership team at Corium could give everyone further updates regarding their sales and marketing planning and how they view the market. That planning remains underway, so the timing will largely be set by Corium's schedule, though beyond that, we'd like to hold it at a favorable point during the fall. Now shifting to more of a reminder slide. Here you have a summary of the KP415 to 484 partnership. Highlighted, as you can see, is the $5 million payment that the NDA acceptance triggered. Roughly $18 million has already come in. Then, regarding what remains to be received — the upcoming milestone is as much as $58 million in approval milestones covering KP415 and 484, with the bulk of that, naturally, tied to KP415. While we keep working toward a possible approval for KP415, our commercial partner, Corium, is doing the same, though at this stage they're planning for the launch. This organization is genuinely well positioned to capitalize on the opportunity sitting before us, given such a differentiated product in KP415. Once more, the organization is led by Perry Sternberg, who spent many years at Shire, serving essentially as Head of Neuroscience and U.S. Commercial there, a role that included the product Vyvanse, a multibillion-dollar ADHD treatment. A number of the other leadership team members likewise are former executives with deep experience in this specific space from their years at Shire. In the slide deck here, we've included a modest update on the ADHD and extended release methylphenidate market as of last year. The market has once again expanded quite steadily year-over-year, at roughly about 4% growth. The branded portion of the market is expanding. That's mostly driven by the Vyvanse piece; however, you can also observe methylphenidate continuing to grow, building on prior years. We remain of the view, once again, that 415 tackles a range of unmet needs, and I'll point those out on the following slide. So, regarding KP415 to 484, here's just a very quick overview for anyone less acquainted with the organization. KP415 and 484 are both the lead products we licensed to GPC, which Corium will now be commercializing. There's a PDUFA date coming up for KP415, and honestly, it pairs with Vyvanse like a left hand with a right hand. The idea is for it to be the methylphenidate counterpart to Vyvanse, which is an amphetamine prodrug; with KP415 specifically, we genuinely observe a faster onset, equal duration, and reduced abuse liability when you look at the prodrug element compared with plain methylphenidate. Our view is that these characteristics, taken together in a market and a therapeutic choice where methylphenidate still needs meaningful enhancements, position this as a possible best-in-class option for ADHD treatment. KP484 is simply the adult formulation of KP415. Some adults genuinely require coverage of their ADHD symptoms throughout the entire day and night, and that is precisely what this product was built to deliver. Discussions continue with Corium regarding what the ideal timing and commitment of resources on their side would look like in order to develop and possibly introduce and commercialize KP484, along with certain other candidate products covered under the licensing arrangement. At this point I'll hand things back to LaDuane so he can speak a bit more about APADAZ commercialization and provide the complete details — essentially the full rundown on the financials. Over to you, LaDuane.
R. Clifton
executiveThanks a lot. Regarding APADAZ, as you're aware, we've licensed that product to KVK Tech, which ranks among the top generic drugmakers in the United States. In fact, they remain the number one producer of generic oxycodone offerings in the country, and they keep — and we are — this latest information comes from them, indicating that the count of Medicaid programs now covering the authorized generic version of APADAZ has grown to 23. That's quite beneficial. And naturally, we've been — the drug has been included on the Federal Supply Schedule, creating more avenues for a range of agencies — federal bodies that make use of it. That said, KVK acknowledges that movement has been sluggish; the climate surrounding opioids is extremely challenging and truly calls for a degree of prudence when it comes to building physician familiarity with the drug and what it might offer their patients. The strategy thus far, however, has centered on delivering education to pharmacies and doctors about, essentially, appropriate opioid prescribing practices. And we're hoping to provide further updates from KVK in the coming months as they keep up those efforts. I can share, somewhat anecdotally, that KVK is strongly dedicated to this product; and even though things have moved more slowly than some might have anticipated, we believe solid headway is being made, and we're eager to pass along those updates as KVK gives them to us. As a brief note, per the licensing deal, there's as much as $3.4 million tied to an initial adoption milestone, plus additional cost reimbursement sums that would be owed to KemPharm once a particular threshold of possible yearly use of APADAZ is reached. Given — drawing on what KVK has communicated to us, we think this might be attained as soon as the close of the year. But once more, we'll keep you informed as things develop. There's also a profit-sharing element in the licensing deal, though given that pricing sits at parity with generics, reaching a certain profit range is essential before any profit share kicks in. So we believe that might occur in 2021. But certainly, some time will need to pass following the milestone being hit before that profit level is reached that would trigger a share flowing to KemPharm. Now shifting to our Q2 financial results. Revenue for Q2 — we recorded $6.9 million, as I noted earlier, made up of the $5 million milestone payment received for the KP415 NDA acceptance along with $1.9 million in services revenue, which we brought in while backing several activities, among them assistance for Corium's commercial preparation work on KP415. We've now seen four quarters in a row where services revenue has grown, and we anticipate that pattern will keep going forward, through and beyond the possible launch of KP415, which, assuming approval, is expected to be aimed at roughly the middle of 2021. Net income for the second quarter came in at just under a million dollars — specifically $900,000, translating to $0.01 per basic and diluted share. That marks a major swing from the same period in 2019, when we posted a net loss of $9.3 million, equal to $0.33 loss per basic and diluted share. Operating income during Q2 2020 reached $2.6 million, helped along both by the top line and by our reduced cost structure. Research and development spending for the quarter totaled $2 million, down 59% compared with Q2 of 2019. Meanwhile, general and administrative costs in the current quarter amounted to $1.7 million — a figure that came in $1.3 million below what we recorded in last year's second quarter. Taking everything into account, the improved figures on the income statement led to more cash on hand when Q2 2020 came to a close. As of June 30, our total cash stood at $6.6 million, which is $4 million more than what we had on March 31 — Q1. Based on our operating forecast, the revenues we expect going forward, and the resources we already have, our cash runway ought to carry us beyond the PDUFA date and all the way to March 31, 2021, when the debt comes due. At the close of Q2, total debt came to $67.3 million, down $1.3 million over the quarter, and that decrease was driven by a $3.2 million reduction from the Deerfield exchanges tied to an agreement we signed back in December of 2019. Those exchanges got offset by two things: $1.3 million in interest added to principal, plus roughly $600,000 from amortization of debt discount and issuance costs. When the quarter closed, about 5.2 million shares were still left under the Deerfield exchange agreement, and that agreement has now been completely used up since the quarter ended. Also during the quarter, we drew down what remained of the Lincoln Park ELOC facility, which brought in an extra $1.1 million in cash. As of the close of Q2, no shares are left under that facility either. Going forward, we keep focusing on strengthening our financial position. As we've noted previously, one of the top items on our agenda is reworking our debt. Alongside our advisors, we're still actively exploring and assessing all the alternatives available to us for reshaping our balance sheet — that could involve royalty-based funding, fresh corporate borrowing, or an arrangement combining multiple elements. Throughout this effort, our aim is to weigh financing expenses against potential dilution so that the outcome we ultimately reach is the best it can be. Although nothing is certain, we still see a path to wrapping this up before the KP415 PDUFA date; and as Dr. As Mickle laid out, multiple catalysts are lined up before that point, and we think they'll bolster these initiatives. Another piece of strengthening our broader financial standing is moving up to NASDAQ. We're pursuing that alongside the other restructuring work — the debt restructuring efforts. Our hope is that everything combined will create momentum and allow us to get back to being listed on the NASDAQ; even so, predicting when such a step could happen is hard. And at a certain stage, these various efforts become tightly connected; we'll update you as we move forward on all of them and make headway in this process. Over to you, Travis.
Travis Mickle
executiveAppreciate that, LaDuane. So, as a way to close things out and offer something of a forward-looking view, you're aware of the PDUFA date. The mid-cycle review meeting takes place tomorrow. That means I'll be putting in serious effort on it this evening. Naturally, we'll share whatever updates arise whenever we become aware of them. Regarding how things stand with Corium, once again, the upcoming update will come straight from them; therefore, we'll get ready for it and deliver it from them at the earliest opportunity. As LaDuane described, the company's financial standing has genuinely been strengthened — once more, we're now quite near breakeven — by generating extra revenue through our consulting arrangement with Corium, along with locating additional chances to keep supporting KP415's commercialization. We're collaborating with Corium too, since at this moment they're putting all their attention on commercialization while also examining the pipeline products, and further updates will come on that front once both companies gain greater clarity; after that, KVK, as LaDuane described, keeps moving APADAZ forward, and I remain very — still enthusiastic about the potential, so let's allow them the opportunity to deliver this adoption milestone to us, ideally before the year is over; though it definitely appears increasingly likely. With all that said, I'd like to close and perhaps check whether there are any further questions.
Oren Livnat
analystCan you hear me?
Travis Mickle
executiveYes.
Oren Livnat
analystOkay, great. Regarding KP415, you received that Day-74 Letter, and it clearly verified the schedule leading up to ADCOM. What I'd like to know is whether anything inside it might shed light — either positively or negatively — on what you anticipate for possible label claims concerning onset and duration? Or would that sort of detail potentially surface, if it surfaces at all, during tomorrow's mid-cycle review meeting? And if that happens, is there any possibility you'd update us — whether good or bad — if your strategy shifts in any way?
Travis Mickle
executiveThe answer is no, and perhaps. On the first portion of what you asked: the Day-74 Letter simply verified the date and laid out that additional meetings would take place. So the product is itself a new molecular entity. Once approved, our expectation is that it will additionally be classified as a new chemical entity; because of that, it falls under what is called the program. That means a highly structured series of milestones and milestone meetings in which the sponsor takes part to some extent; so this initial mid-cycle review meeting is one we will now be holding with the agency tomorrow, and during that they might simply raise subjects for conversation where they could ask you for further information; however, as things stand right now, we possess nothing that truly signals how that labeling might appear; at some stage, though, that will shift. We are in fact prohibited from revealing those discussions; at some point, perhaps, contingent on how that develops, we might offer some sense of where we could be positioned, yet we cannot provide any specifics about them. That said, it would come nearer — far nearer to the PDUFA date than where we are now in August.
Oren Livnat
analystAll right. And I believe each time we speak, I ask you something in this vein, which concerns how visible Corium is; and it was encouraging to learn about the call event they are, hopefully, going to hold; yet beyond the investor community, how about the ADHD treatment community? Given a possible approval in the not-so-distant future, ought we to anticipate that a company would be informing the industry about this product that might arrive with this theoretical profile and perhaps also informing the industry about their corporate presence?
Travis Mickle
executiveHonestly, that question belongs to Corium, but I will — I definitely will not speculate about all of their plans. Based on my understanding, they're busy getting the market ready and laying the groundwork for a release. If we calculate it out and treat March 2 as the PDUFA date, it's worth remembering that 70% of what we've got is a prodrug of methylphenidate that isn't scheduled yet and needs to be. By law, that takes 90 days with the DEA. That points us toward a possible launch around the middle of the year, which, as you might guess, lines up nicely with when school begins. So to the best of what I know, I believe they're pulling out all the stops right now to get ready for that. That said, you're right. As we move forward, activity levels are going to keep rising. That includes things like medical meetings and symposia involving key opinion leaders, various events, efficacy-focused panels — anything permissible before a green light is given, followed by all the usual efforts once that happens.
Oren Livnat
analystOkay, that sounds good, and I'm eager to see it. As for KP484, it clearly seems like the ball's in their court regarding what comes next, but am I right to think nothing will move on that front until there's greater clarity regarding 415? Is there any basis for believing that no matter how things shake out with 415 on the regulatory side, that outcome carries a direct implication for 484? I suppose if the FDA identified serious issues with the prodrug itself, then yes, that would clearly carry over, though the two involve somewhat different approaches; so I'm curious whether any work can be done on that product in the interim.
Travis Mickle
executiveHonestly, that's something I'd like to ask Corium as well. When will you begin development on KP484? That's an area where I simply lack further insight, and they'll let us know whenever they choose to, more or less. Nothing I've seen suggests any worry stemming from how 415 interacts or anything like that; so they're reaching their own conclusions. Their priority is getting this company prepared to launch 415, and afterward determining what role 484 might play. That isn't to say they won't begin far ahead of time, but we haven't been informed that this is happening as of yet.
Travis Mickle
executiveThanks. And I appreciate all of you being here today. Once again, we keep moving forward; we keep executing according to our strategy. And whenever developments occur, we'll share them as promptly as we can. I'm grateful for your backing, your ongoing attention to this business, and I anticipate even greater accomplishments soon. Thanks to each of you.
Operator
operatorEveryone, that brings us to the end of today's conference call. We appreciate you joining in. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Zevra Therapeutics, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Zevra Therapeutics, Inc. earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Zevra Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.